

University of Groningen

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

the THAOS investigators; Dispenzieri, Angela; Coelho, Teresa; Conceição, Isabel; Waddington-Cruz, Márcia; Wixner, Jonas; Kristen, Arnt V.; Rapezzi, Claudio; Planté-Bordeneuve, Violaine; Gonzalez-Moreno, Juan

Published in:

Orphanet journal of rare diseases

DOI:

[10.1186/s13023-022-02359-w](https://doi.org/10.1186/s13023-022-02359-w)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

the THAOS investigators, Dispenzieri, A., Coelho, T., Conceição, I., Waddington-Cruz, M., Wixner, J., Kristen, A. V., Rapezzi, C., Planté-Bordeneuve, V., Gonzalez-Moreno, J., Maurer, M. S., Grogan, M., Chapman, D., & Amass, L. (2022). Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. *Orphanet journal of rare diseases*, 17(1), [236]. <https://doi.org/10.1186/s13023-022-02359-w>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH

Open Access



Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

Angela Dispenzieri^{1*} , Teresa Coelho², Isabel Conceição³, Márcia Waddington-Cruz⁴, Jonas Wixner⁵, Arnt V. Kristen⁶, Claudio Rapezzi^{7,8}, Violaine Planté-Bordeneuve⁹, Juan Gonzalez-Moreno¹⁰, Mathew S. Maurer¹¹, Martha Grogan¹², Doug Chapman¹³ and Leslie Amass¹³ on behalf of the THAOS investigators

Abstract

Background: Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disease caused by the accumulation of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in the heart, peripheral nerves, and other tissues and organs.

Methods: Established in 2007, the Transthyretin Amyloidosis Outcomes Survey (THAOS) is the largest ongoing, global, longitudinal observational study of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic carriers of pathogenic *TTR* mutations. This descriptive analysis examines baseline characteristics of symptomatic patients and asymptomatic gene carriers enrolled in THAOS since its inception in 2007 (data cutoff: August 1, 2021).

Results: This analysis included 3779 symptomatic patients and 1830 asymptomatic gene carriers. Symptomatic patients were predominantly male (71.4%) and had a mean (standard deviation [SD]) age of symptom onset of 56.3 (17.8) years. Val30Met was the most common genotype in symptomatic patients in South America (80.9%), Europe (55.4%), and Asia (50.5%), and more patients had early- versus late-onset disease in these regions. The majority of symptomatic patients in North America (58.8%) had ATTRwt amyloidosis. The overall distribution of phenotypes in symptomatic patients was predominantly cardiac (40.7%), predominantly neurologic (40.1%), mixed (16.6%), and no phenotype (2.5%). In asymptomatic gene carriers, mean (SD) age at enrollment was 42.4 (15.7) years, 42.4% were male, and 73.2% carried the Val30Met mutation.

Conclusions: This 14-year global overview of THAOS in over 5000 patients represents the largest analysis of ATTR amyloidosis to date and highlights the genotypic and phenotypic heterogeneity of the disease.

ClinicalTrials.gov Identifier: NCT00628745.

Keywords: Amyloidosis, Cardiomyopathy, Polyneuropathy, Transthyretin, Registry

Introduction

Transthyretin amyloidosis (ATTR amyloidosis) is a multi-systemic, life-threatening disease resulting from the deposition of transthyretin (TTR) amyloid fibrils in the heart, peripheral nerves, and other tissues, leading mainly to polyneuropathy and/or cardiomyopathy [1]. There are two distinct forms of ATTR amyloidosis: hereditary or

*Correspondence: dispenzieri.angela@mayo.edu

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA
Full list of author information is available at the end of the article



variant ATTR amyloidosis (ATTRv amyloidosis), which is caused by pathogenic mutations that destabilize the TTR protein, and wild-type ATTR amyloidosis (ATTRwt amyloidosis), which results from the accumulation of wild-type TTR protein [2, 3]. The phenotypic presentation of ATTRv amyloidosis is variable and can be predominantly neurologic, predominantly cardiac, or a mix of both neurologic and cardiac manifestations, depending on the particular *TTR* variant and other factors [2, 4]. So far, over 140 *TTR* variants have been identified [5]. ATTRwt amyloidosis most often presents as cardiomyopathy [3].

ATTR amyloidosis is a progressive disease with a poor prognosis when left untreated. Life expectancy ranges between 2 and 10 years after symptom onset and depends upon disease type and other factors [2, 3, 6]. Obtaining an accurate diagnosis of ATTR amyloidosis can be difficult due to the heterogeneity of the disease, low disease awareness, and clinical features that overlap with more common disorders [2, 6, 7]. Improved understanding of the disease can facilitate earlier identification and intervention with approved disease-modifying therapies.

Established in 2007, the Transthyretin Amyloidosis Outcomes Survey (THAOS) is the largest ongoing, global, longitudinal observational study of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic carriers of pathogenic *TTR* mutations (NCT00628745) [8]. By studying a large, global patient population, THAOS has provided valuable insights into ATTR amyloidosis and has highlighted the genotypic, phenotypic, and geographic heterogeneity of the disease [9–13]. The objective of this descriptive analysis was to examine baseline characteristics of symptomatic patients with ATTR amyloidosis and asymptomatic gene carriers enrolled in THAOS since its inception 14 years ago.

Methods

Study design and patient population

The study design and eligibility criteria of THAOS have been described [8]. All study sites received ethical or institutional review board approval prior to patient enrollment, and each patient provided written informed consent. The study followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki.

The analysis population consisted of all patients enrolled in THAOS (data cutoff date: August 1, 2021). Symptomatic patients were those with at least one symptom reported as definitely related to ATTR amyloidosis at enrollment. Asymptomatic gene carriers were those with a pathogenic disease-causing *TTR* genetic variant and no definitely ATTR amyloidosis-related symptom at enrollment, with the requirement that all symptoms be

assessed at enrollment. Patients with no definitely ATTR amyloidosis-related symptoms at enrollment who were not assessed for all symptoms were considered to have a missing symptomatic status.

Demographics, clinical characteristics, and patient-reported outcomes collected at enrollment were analyzed in the overall cohort of symptomatic patients and by the following genotype subgroups: ATTRwt amyloidosis; Val30Met with early-onset disease (age \leq 50 years, based on age at diagnosis); Val30Met with late-onset disease (age $>$ 50 years); ‘cardiac mutations’ (Val122Ile [p.Val142Ile] [14], Leu111Met [p.Leu131Met] [15], Thr60Ala [p.Thr80Ala] [16], and Ile68Leu [p.Ile88Leu] [17]); and non-Val30Met excluding cardiac mutations.

Phenotype at enrollment was further analyzed in symptomatic patients by region (North America, South America, Europe, and Asia). Phenotype categories were defined as follows: Predominantly cardiac included patients with at least one of the following symptoms: heart failure, dyspnea, or abnormal electrocardiogram due to rhythm disturbance, and no more than mild neurologic or gastrointestinal (GI) symptoms (excluding erectile dysfunction, constipation, and carpal tunnel syndrome); cardiac symptoms did not need to be ongoing at a given visit. Predominantly neurologic included patients with neurologic or GI symptoms of any severity without heart failure, dyspnea, or abnormal electrocardiogram due to rhythm disturbance; neurologic and GI symptoms had to be ongoing. Mixed included patients with heart failure, dyspnea, or abnormal electrocardiogram due to rhythm disturbance and neurologic or GI symptoms of any severity but did not satisfy the criteria for predominantly cardiac or predominantly neurologic. No phenotype included all other symptomatic patients who did not meet criteria for any of these phenotypes. All patients with ATTRwt amyloidosis were classified as predominantly cardiac unless they had any neurologic symptoms definitely related to ATTR amyloidosis, in which case they were classified as mixed phenotype.

Symptoms at baseline were categorized as autonomic neuropathy, cardiac disorder, gastrointestinal manifestations, motor neuropathy, sensory neuropathy, and other. Autonomic neuropathy included dizziness, palpitations, dry eye, constipation, diarrhea, diarrhea/constipation, early satiety, fecal incontinence, nausea, vomiting, recurrent urinary tract infections, urinary incontinence, urinary retention, dyshidrosis, and erectile dysfunction; cardiac disorder included coronary artery disease, dyspnea, heart failure, myocardial infarction, rhythm disturbance, syncope, arterial hypertension, cardiomyopathy, and other cardiovascular disease. Gastrointestinal manifestations included constipation, diarrhea, diarrhea/constipation, early satiety, fecal incontinence, nausea,

unintentional weight loss, and vomiting. Motor neuropathy included muscle weakness and walking disability. Sensory neuropathy included balance abnormality, neuropathic arthropathy, neuropathic pain/paresthesia, numbness, temperature or pain insensitivity, and tingling. Symptom categories were not mutually exclusive.

Demographics collected at enrollment were also analyzed in the overall cohort of asymptomatic gene carriers and by genotype category (Val30Met, cardiac mutations, and non-Val30Met excluding cardiac).

Assessments

Patients' ability to perform normal daily life activities and their need for assistance was assessed in symptomatic patients using the Karnofsky Performance Status Scale score, ranging from 10 (moribund; fatal processes progressing rapidly) to 100 (normal; no complaints). Neurologic impairment was measured in symptomatic patients using the derived Neuropathy Impairment Score in the Lower Limbs (NIS-LL; ranges from 0 to 88) [18]. Higher scores indicate greater impairment, and the NIS-LL scale includes reflex, motor, and sensory subscales. Modified Polyneuropathy Disability (mPND) scores were analyzed in symptomatic patients with a predominantly neurologic or mixed phenotype. The mPND score is a measure of walking disability and ranges from 0 to IV, where 0 indicates no sensory disturbances in the feet and able to walk without difficulty; I indicates sensory disturbance in the feet but preserved walking capacity; II indicates some difficulties walking, but can walk without aid; IIIa indicates 1 stick or crutch required for walking; IIIb indicates 2 sticks or crutches required for walking; and IV indicates patients confined to a wheelchair or bed.

Measures of cardiac disease in symptomatic patients were left ventricular (LV) septal thickness and LV ejection fraction. Additional cardiac findings, including troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and New York Heart Association (NYHA) functional class, were analyzed in symptomatic patients with a predominantly cardiac or mixed phenotype.

Quality of life (QoL) was assessed in symptomatic patients using the EQ-5D-3L and the Norfolk Quality of Life – Diabetic Neuropathy questionnaire. The EQ-5D-3L is a measure of self-reported health status. The first part assesses health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with three levels: no problems, some problems, extreme problems/unable to. Health state profiles are assigned a summary index score ranging from 0 (death) to 1 (perfect health). The second part is a visual analog scale on which participants rate perceived health from 0 (worst) to 100 (best). The 35-item Norfolk Quality of Life – Diabetic Neuropathy questionnaire assesses

diabetic neuropathy across five domains: physical functioning/large fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. Scores range from – 4 to 136, with higher scores indicating worse QoL.

Statistical analyses

This was a descriptive analysis. Continuous data are presented as mean (standard deviation [SD]) or median (10th, 90th percentile), and categorical data are presented as count (percentage).

Results

Demographics and genotype

There were 5894 patients from 84 study sites in 23 countries enrolled in THAOS at the data cutoff date (Fig. 1). Of these, 3779 were symptomatic patients, 1830 were asymptomatic gene carriers, and 61 were missing symptomatic status. Val30Met was the most prevalent genotype among all THAOS patients (49.6%), followed by ATTRwt amyloidosis (23.5%) and Val122Ile (6.0%) (Additional file 1). Val30Met was most common in Europe (64.6%), South America (80.3%), and Japan (74.0%), and wild-type disease was most common in North America (54.8%). Within Europe, non-Val30Met or cardiac mutations were more common in some individual countries (Bulgaria, Denmark, Israel, Italy, the Netherlands, Romania, and Turkey), but Val30Met was the predominant genotype overall.

Symptomatic patients were predominantly male across all genotype subgroups (Table 1). Overall, the mean age at symptom onset was 56.3 years and was higher in patients with ATTRwt amyloidosis compared with the other genotype subgroups. Mean time from symptom onset to diagnosis was 4.0 years in all symptomatic patients and ranged from 2.0 years in the early-onset Val30Met subgroup to 4.7 years in the ATTRwt amyloidosis subgroup. The majority of patients in North America had ATTRwt amyloidosis (58.8%). Val30Met was the most common genotype in South America (80.9%), Europe (55.4%), and Asia (50.5%), and more patients had early-versus late-onset disease in each of these regions (Fig. 2a; Additional file 2).

Of the 1830 asymptomatic gene carriers, 42.4% were male and 73.2% carried the Val30Met mutation (Table 2). Mean age at enrollment was 42.4 years and was higher in asymptomatic gene carriers with cardiac mutations than those in the other genotype subgroups.

Distribution of phenotypes at enrollment in symptomatic patients

The overall phenotype distribution for symptomatic patients at enrollment was predominantly




Table 1 Demographics of symptomatic patients according to genotype category


	Overall (n = 3779)	ATTRwt amyloidosis (n = 1156)	Val30Met early onset (n = 826)	Val30Met late onset (n = 588)	Cardiac mutations (n = 384)	Non-Val30Met excluding cardiac (n = 697)
Male, n (%)	2698 (71.4)	1086 (93.9)	447 (54.1)	381 (64.8)	284 (74.0)	429 (61.5)
Race/ethnicity ^a , n (%)						
Caucasian	2083 (76.6)	961 (94.4)	183 (67.3)	336 (86.6)	157 (46.0)	397 (65.4)
African descent	269 (9.9)	30 (2.9)	26 (9.6)	16 (4.1)	164 (48.1)	28 (4.6)
American Hispanic	15 (0.6)	1 (0.1)	8 (2.9)	0	2 (0.6)	3 (0.5)
Latino American	124 (4.6)	5 (0.5)	18 (6.6)	4 (1.0)	15 (4.4)	78 (12.9)
Asian	218 (8.0)	15 (1.5)	37 (13.6)	31 (8.0)	2 (0.6)	99 (16.3)
Other	11 (0.4)	6 (0.6)	0	1 (0.3)	1 (0.3)	2 (0.3)
Age at enrollment (years), mean (SD)	62.3 (17.0)	77.5 (7.1)	39.8 (7.9)	67.9 (8.3)	69.3 (9.1)	56.9 (12.6)
Age at onset of ATTR amyloidosis symptoms (years), n	3775	1156	826	588	383	694
Mean (SD)	56.3 (17.8)	72.0 (9.7)	33.1 (6.5)	61.8 (9.3)	63.5 (11.3)	50.9 (12.6)
Time from symptom onset to diagnosis (years), n	3492	1092	826	588	347	639
Mean (SD)	4.0 (5.9)	4.7 (6.9)	2.0 (3.0)	4.4 (5.0)	4.6 (6.7)	4.6 (6.5)
Follow-up time ^b (years), mean (SD)	3.6 (3.0)	2.0 (1.8)	6.2 (3.0)	3.9 (2.7)	2.4 (2.2)	3.1 (2.6)

Val30Met early onset and late onset n based on all patients with available data for disease diagnosis; 128 patients with Val30Met were missing date of diagnosis. Symptom onset was the date of first occurrence of symptom(s) reported as definitely related to ATTR amyloidosis. Cardiac mutations include Val122Ile, Leu111Met, Thr60Ala, and Ile68Leu

^a Denominator for race/ethnicity is the total of non-missing records

^b Follow-up time is based on all patients, from enrollment to last observation

ATTR amyloidosis = transthyretin amyloidosis; ATTRv amyloidosis = hereditary transthyretin amyloidosis; ATTRwt amyloidosis = wild-type transthyretin amyloidosis; SD = standard deviation



cardiac (40.7%), predominantly neurologic (40.1%), mixed (16.6%), and no phenotype (2.5%) (Additional file 2). Predominantly cardiac was the most common phenotype at enrollment in North America, whereas predominantly neurologic was the most common phenotype at enrollment in Europe, South America, and Asia (Fig. 3a; Additional file 2).

ATTRwt amyloidosis comprised most of the predominantly cardiac phenotype patients in North America and Europe (Fig. 2b). For Asia and South America, respectively, the non-Val30Met excluding cardiac and cardiac mutations genotype subgroups were most common among the predominantly cardiac phenotype (Fig. 2b). The only region in which Val30Met (early or late onset) did not account for the majority of the predominantly

neurologic phenotype was North America (Fig. 2c). More than half of patients with a mixed phenotype from Asia had non-Val30Met excluding cardiac as their genotype; 38.5% of the mixed phenotype in North America consisted of ATTRwt patients (Fig. 2d).

Most symptomatic patients with Val30Met had a predominantly neurologic phenotype at enrollment (72.8%) (Additional file 2). The Val30Met late- versus early-onset group had a greater proportion of mixed (24.1% vs 13.6%) and predominantly cardiac (10.9% vs 3.3%) (Fig. 4; Additional file 2). Most symptomatic patients with ATTRwt amyloidosis had a predominantly cardiac phenotype (89.0%), with 9.8% of patients with ATTRwt amyloidosis presenting with a mixed phenotype (Fig. 4; Additional file 2). The distribution of phenotypes in early-onset

Table 2 Demographics of asymptomatic gene carriers according to genotype category

	Overall (n = 1830)	Val30Met (n = 1339)	Cardiac mutations (n = 200)	Non-Val30Met excluding cardiac (n = 291)
Male, n (%)	776 (42.4)	514 (38.4)	115 (57.5%)	147 (50.5)
Race/ethnicity ^a , n (%)				
Caucasian	677 (77.9)	384 (87.3)	113 (60.1)	180 (74.7)
African descent	103 (11.9)	27 (6.1)	68 (36.2)	8 (3.3)
American Hispanic	11 (1.3)	7 (1.6)	2 (1.1)	2 (0.8)
Latino American	40 (4.6)	8 (1.8)	5 (2.7)	27 (11.2)
Asian	33 (3.8)	12 (2.7)	0	21 (8.7)
Other	5 (0.6)	2 (0.5)	0	3 (1.2)
Age at enrollment (years), mean (SD)	42.4 (15.7)	39.3 (14.5)	57.3 (16.1)	46.0 (14.1)

Cardiac mutations include Val122Ile, Leu111Met, Thr60Ala, and Ile68Leu

^a Denominator for race/ethnicity is the total of non-missing records

SD = standard deviation

Val30Met and wild-type patients was generally consistent across global regions (Fig. 3b, c; Additional file 2). Slightly higher rates of predominantly cardiac phenotypes were observed in the North American late-onset Val30Met group than other regions with the same late-onset Val30Met mutation (Fig. 3d). Patients with cardiac mutations had a predominantly neurologic phenotype in 16.7% and a mixed phenotype in 17.2% of patients (Fig. 4; Additional file 2). The large proportion of patients with cardiac mutations who had a predominantly neurologic or mixed phenotype was most notable in the Asian and South American groups (Fig. 3e), though sample sizes were small. Among the non-Val30Met excluding cardiac mutations genotype group, patients from South America were most likely to have a mixed phenotype and least likely to have a predominantly cardiac phenotype (Fig. 3f; Additional file 2).

Clinical characteristics at enrollment in symptomatic patients

Greater neurologic impairment was observed in the Val30Met and non-Val30Met excluding cardiac subgroups (Additional file 3). Patients with late-onset Val30Met had the highest neurologic impairment as measured by the NIS-LL. Greater cardiac impairment was observed in patients with ATTRwt amyloidosis or cardiac mutations (Additional file 3).

Over half of symptomatic patients presented with sensory neuropathy (59.9%), cardiac disorder (59.4%), and/or autonomic neuropathy (50.1%) at enrollment. GI manifestations were present in 38.3% of patients, and motor neuropathy in 29.2% of patients. Cardiac disorder was the most common presenting symptom at enrollment in patients with ATTRwt amyloidosis or cardiac mutations,

whereas sensory neuropathy was the most common presenting symptom in all other genotype subgroups (Fig. 5). Autonomic neuropathy and GI symptoms were more common in Val30Met early-onset as compared to late-onset patients, while motor neuropathy and cardiac disorder were more common in late-onset as compared to early-onset patients.

Cardiac characteristics at enrollment in symptomatic patients with a predominantly cardiac or mixed phenotype

In the subset of patients with a predominantly cardiac or mixed phenotype, heart failure was present in 92.2% of patients with cardiac mutations, 88.6% of patients with ATTRwt amyloidosis, and 62.5% of patients with other mutations (Table 3). A greater proportion of patients with ATTRwt amyloidosis had an abnormal electrocardiogram, atrial fibrillation/flutter, and a pacemaker implanted than those with cardiac and other mutations.

Neurologic characteristics at enrollment in symptomatic patients with a predominantly neurologic or mixed phenotype

Most patients with a predominantly neurologic or mixed phenotype had a score of I (52.1%) or II (20.7%) on the mPND (Additional file 4). Patients with Val30Met late-onset disease had greater walking impairment than those with Val30Met early-onset disease (mPND > II, 28.3% vs 8.0%).

Discussion

This 14-year global overview of THAOS in over 5000 symptomatic patients with ATTR amyloidosis and asymptomatic gene carriers represents the largest descriptive analysis of the disease to date. Significant





Fig. 3 Regional distribution of phenotype at enrollment in symptomatic patients. The proportion of patients with each phenotype shown by region in **a** the overall population of symptomatic patients and by genotype category, **b** ATTRwt amyloidosis, **c** Val30Met early onset, **d** Val30Met late onset, **e** cardiac mutations, and **f** non-Val30Met excluding cardiac mutations. The sum of values for each region in each figure equals one. Val30Met early onset and late onset *n* based on all patients with available data for disease diagnosis; 128 patients with the Val30Met mutation and no date of disease diagnosis were not included in the genotype category breakdown. Cardiac mutations include Val122Ile, Leu111Met, Thr60Ala, and Ile68Leu. ATTRwt amyloidosis = wild-type transthyretin amyloidosis



regional variation was observed in the distribution of genotypes and phenotypes. Val30Met was the most frequent variant genotype, and predominantly neurologic was the most frequent phenotype, in Europe, Asia, and South America, reflecting the endemic foci within these regions [2]. Alternatively, ATTRwt amyloidosis and cardiac mutations were the most common genotypes, and predominantly cardiac the most common phenotype, in North America, consistent with previously reported data [13].

Male predominance was observed in symptomatic patients across all genotypes, but most notably in patients with ATTRwt amyloidosis and cardiac mutations. These findings are consistent with the male predominance observed in ATTRwt amyloidosis, wherein men account for >80% of diagnosed cases [22]. Mitochondrial DNA and neurohormonal factors may explain these sex-related differences [23, 24], although further studies are needed to clarify the role of these factors in the development of the disease. Although the proportion of males was greater than that of females in the early-onset Val30Met subgroup, the difference was not as great for this genotype subgroup (male, 54.1%;




Table 3 Cardiac characteristics at enrollment in symptomatic patients with a predominantly cardiac or mixed phenotype according to genotype category

	ATTRwt amyloidosis (n = 1142)	Cardiac mutations (n = 307)	Other mutations (n = 718)
Heart failure, n (%)	1012 (88.6)	283 (92.2)	449 (62.5)
NYHA functional class ^a , n (%)			
I	107 (10.5)	27 (9.5)	78 (17.4)
II	612 (59.8)	140 (49.3)	220 (49.1)
III	278 (27.2)	102 (35.9)	133 (29.7)
IV	26 (2.5)	15 (5.3)	17 (3.8)
Abnormal ECG, n (%)	947 (82.9)	218 (71.0)	415 (57.8)
Atrial fibrillation/flutter, n (%)	420 (36.8)	56 (18.2)	53 (7.4)
Pacemaker implanted, n (%)	179 (15.7)	26 (8.5)	33 (4.6)
ICD implanted, n (%)	59 (5.2)	16 (5.2)	12 (1.7)
NT-proBNP (pg/mL), n	775	127	253
Median (10th, 90th percentile)	2573.0 (731.0, 9041.0)	2648.0 (664.0, 8889.0)	1557.0 (213.0, 8633.0)
Troponin I (ng/mL), n	133	57	58
Median (10th, 90th percentile)	0.1 (0.0, 0.3)	0.1 (0.0, 0.5)	0.1 (0.0, 0.6)
Troponin T (ng/mL), n	626	86	215
Median (10th, 90th percentile)	0.1 (0.0, 0.2)	0.1 (0.0, 0.3)	0.0 (0.0, 0.1)

Cardiac mutations include Val122Ile, Leu111Met, Thr60Ala, and Ile68Leu. Other mutations include Val30Met and non-Val30Met excluding cardiac mutations

^a Denominator for NYHA functional class is the total of non-missing records

ATTRwt amyloidosis = wild-type transthyretin amyloidosis; ECG = electrocardiogram; ICD = implantable cardioverter-defibrillator; NP-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; SD = standard deviation

female, 45.9%). These results are in line with a prior report from a nationwide survey in Japan wherein the numbers of males and females with early-onset Val30Met disease were similar [19].

On the other hand, female predominance was observed among asymptomatic gene carriers. Prior reports suggest a later age of onset and lower disease penetrance in females, particularly in regard to cardiac manifestations [20, 21], and, therefore, females would be expected to represent a larger proportion of asymptomatic gene carriers.

Accurate diagnosis of ATTR amyloidosis can often be delayed for years. In this report, diagnosis of ATTR amyloidosis occurred an average of 4 years following symptom onset, with the longest time to diagnosis seen in patients with ATTRwt amyloidosis. Diagnosing ATTRwt amyloidosis can be particularly challenging because cardiac symptoms are often consistent with more common types of heart failure, and historically a diagnosis has been obtained through endomyocardial biopsy, an invasive and expensive technique [6, 25]. It is expected that increased use of bone scintigraphy, a minimally invasive and less expensive diagnostic tool, would decrease the time to diagnosis among these patients [3, 6], although this effect has not yet been reflected in THAOS [26]. Patients with early-onset Val30Met disease had the shortest time to diagnosis, but there was still an average

2 years from symptom onset to obtain a diagnosis despite most of these patients being from countries with endemic foci. This delay reflects the insidious onset of non-specific symptoms and underscores the need for objective biomarkers of onset and regular monitoring of asymptomatic carriers of pathogenic *TTR* mutations. Early identification of ATTR amyloidosis has become increasingly important with the recent approval of a number of disease-modifying therapies, including transthyretin stabilizers [27], small interfering RNA [28], and antisense oligonucleotides [29].

A mixed phenotype was observed in nearly 20% of symptomatic patients with Val30Met and cardiac mutations, and in ~10% of symptomatic patients with ATTRwt amyloidosis. Furthermore, patients presented with a variety of symptoms at enrollment. Autonomic neuropathy and/or sensory neuropathy were reported in ~15% of patients with ATTRwt amyloidosis and over one-third of patients with cardiac mutations, despite these mutations being associated primarily with cardiomyopathy. The majority of patients with Val30Met presented with sensory and autonomic neuropathy and GI manifestations. Motor neuropathy and cardiac disorder were also seen in a substantial proportion of Val30Met patients, with higher rates in those with late- versus early-onset disease. There has been increasing awareness of the multisystemic nature of ATTR amyloidosis, and the mixed phenotype

may be more common than previously thought, including in patients with ATTRwt amyloidosis and with variants denoted as cardiac mutations in this analysis [12, 30–32]. Notably, 17% of patients with variants denoted as cardiac mutations had a predominantly neurologic phenotype. These findings are in line with recent reports of significant neurologic involvement in patients with mutations traditionally considered primarily cardiac [31].

The wide spectrum of symptoms observed at enrollment and the substantial proportion of patients with a mixed phenotype in this analysis emphasize the need for a multidisciplinary approach to the management of patients with all types of ATTR amyloidosis [33], and the importance of comprehensive evaluation, including neurologic, neurophysiological, and cardiac (electrocardiogram and echocardiogram) examinations. As evident in this study population, ATTR amyloidosis is a highly heterogeneous disease, and clinical manifestations can vary between different variants and/or geographic regions, and even between different family members who share the same pathogenic mutation.

Strengths and limitations

A strength of the study was the inclusion of over 5000 patients from 23 countries, making this the largest descriptive analysis of ATTR amyloidosis to date. As with any disease registry, under-reporting of disease characteristics and under-ascertainment of patients are potential limitations that also apply to this THAOS analysis. Furthermore, the selection of patients included in THAOS may be biased, as there is an uneven distribution of specialties among investigators and study sites in some countries, and this could influence the phenotypic distribution across regions. For example, European patients are predominantly from Portugal, where two neurologic sites are the primary contributors of patients; and in the United States, cardiac sites are more common than neurologic sites. However, a prior analysis examined the relationship between the specialty of the investigator and the phenotype distribution of patients and found that, with a few exceptions, this relationship was not as strong as expected [12]. THAOS is a real-world registry so the proportion of neurologic, cardiologic, and other types of investigators will reflect the actual distribution of where patients with suspected ATTR amyloidosis are referred. There could also be under-reporting of mixed phenotypes in the earlier years of THAOS, before centers were consistently conducting comprehensive neurologic and cardiac assessments of all patients.

Conclusion

This analysis of over 5000 symptomatic patients and asymptomatic *TTR* gene carriers demonstrates the wide heterogeneity and increasing awareness of ATTR amyloidosis. Although ATTR amyloidosis has historically been considered a primarily neurologic or a primarily cardiac disease, a mixed phenotype and multisystemic involvement are increasingly described. These findings highlight the need for a consistent, multidisciplinary approach to the management of ATTR amyloidosis.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13023-022-02359-w>.

Additional file 1: Table 1. Most frequent genotypes recorded at enrollment in the overall population.

Additional file 2: Table 2. Distribution of phenotype in symptomatic patients according to genotype category.

Additional file 3: Table 3. Clinical characteristics and patient-reported outcomes in symptomatic patients according to genotype category.

Additional file 4: Table 4. Neurologic findings in symptomatic patients with a predominantly neurologic or mixed phenotype.

Acknowledgements

We thank all THAOS patients and investigators for their important contributions to this study. Medical writing support was provided by Emily Balevich, PhD, of Engage Scientific Solutions and was funded by Pfizer.

Author contributions

All authors contributed to the design and conduct of the analysis; interpretation of the data; and preparation, review, and approval of the manuscript.

Funding

The THAOS registry and this analysis were sponsored by Pfizer. Pfizer contributed to the study design and management and collection of data. In their role as authors, employees of Pfizer were involved in the interpretation of data, preparation, review, and approval of the manuscript and the decision to submit for publication, along with their co-authors. The study sponsors approved the manuscript from an intellectual property perspective but had no right to veto the publication.

Availability of data and materials

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See <https://www.pfizer.com/science/clinical-trials/trial-data-and-results> for more information.

Declarations

Ethics approval and consent to participate

All THAOS sites received ethical or institutional review board approval prior to patient enrollment, and each patient provided written informed consent. The study followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

AD reports research grants from Celgene, Millennium, Pfizer, Janssen, and Alnylam; and has received funding from Pfizer for meeting expenses (travel).

and attended advisory boards for Akcea and Intellia. TC reports serving as a medical advisor for Pfizer and receiving funding for scientific meeting expenses (travel, accommodation, and registration) from Pfizer. IC reports consulting fees and funding for scientific meeting expenses (travel, accommodation, and registration) from Pfizer. MW-C reports research funding, consulting fees, and travel support for advisory boards and meetings from FoldRx Pharmaceuticals and Pfizer. JW reports consulting fees and travel support for lectures and advisory boards from Pfizer and Alnylam, and consulting fees from Akcea. AVK reports reimbursement for study visits from Pfizer during the conduct of the study. CR reports research grants from Pfizer and consultancy fees from Pfizer, Alnylam, and Prothena. VP-B reports serving as a medical advisor for Pfizer, Alnylam, Eidos, and Ionis. JG-M reports speaker fees from Pfizer, Alnylam, and Akcea. MSM reports grants from Pfizer during the conduct of the study; grants and personal fees from Pfizer, Eidos, Prothena, and Ionis; grants from Alnylam; and personal fees from GSK and Akcea outside the submitted work. MG reports grants and advisory board and consultancy fees paid to her institution from Alnylam, Eidos, Prothena, and Pfizer. DC and LA are full-time employees of Pfizer and hold stock and/or stock options with Pfizer.

Author details

¹Division of Hematology, Mayo Clinic, Rochester, MN, USA. ²Unidade Corino Andrade, Hospital Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal. ³Department of Neurosciences, CHULN, Hospital de Santa Maria, Universidade de Lisboa, Lisbon, Portugal. ⁴University Hospital, Federal University of Rio de Janeiro, National Amyloidosis Referral Center, CEPARM, Rio de Janeiro, Brazil. ⁵Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. ⁶Department of Cardiology, Angiology, Respiratory Medicine, Medical University of Heidelberg, Heidelberg, Germany. ⁷Cardiological Centre, University of Ferrara, Ferrara, Italy. ⁸Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy. ⁹Hôpital Henri Mondor – AP-HP, East Paris University, Créteil, France. ¹⁰Servicio de Medicina Interna, Hospital Universitario Son Llatzer, Instituto de Investigación Sanitaria Illes Balears, Palma de Mallorca, Spain. ¹¹Columbia University College of Physicians and Surgeons, New York, NY, USA. ¹²Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. ¹³Pfizer Inc, New York, NY, USA. ¹⁴Hospital Universitario Puerta de Hierro, Majadahonda, Spain. ¹⁵Alexandrovska University Hospital Clinic of Neurology, Sofia, Bulgaria. ¹⁶Hospital Universitari de Bellvitge, Barcelona, Spain. ¹⁷Instituto Nacional de Ciencia Médicas y Nutrición Salvador Zubiran, Distrito Federal, Mexico. ¹⁸Universitätsklinikum Muenster – Transplant Hepatology, Muenster, Germany. ¹⁹University of Pennsylvania – Perelman Center for Advanced Medicine, Philadelphia, PA, USA. ²⁰FLENI, Ciudad Autónoma de Buenos Aires, Argentina. ²¹Kumamoto University, Kumamoto-City, Japan. ²²CHU de Toulouse – Hôpital Rangueil, Toulouse, France. ²³Shinshu University School of Medicine, Matsumoto, Japan. ²⁴AOU Policlinico G. Martino – Messina – Dr. Vita, Messina, Italy. ²⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. ²⁶Cleveland Clinic Foundation, Cleveland, OH, USA. ²⁷Vanderbilt University School of Medicine, Nashville, TN, USA. ²⁸Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy. ²⁹The Ohio University College of Medicine, Columbus, OH, USA. ³⁰Hospital Juan Ramon Jimenez, Huelva, Spain. ³¹CHU de Bicêtre, Paris, France. ³²Aarhus University Hospital, Skejby, Aarhus, Denmark. ³³Karolinska University Hospital, Stockholm, Sweden. ³⁴Azienda Ospedaliero-Universitaria Di Careggi, Florence, Italy. ³⁵University Medical Center Groningen, Groningen, The Netherlands. ³⁶Institut Clinic de Nefrologia i Urologia – ICNU, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain. ³⁷CHU de Fort-de-France, Fort-de-France, France. ³⁸Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA. ³⁹Fondazione Toscana Gabriele Monasterio Per La Ricerca Medica E Di Sanità Pubblica, Pisa, Italy. ⁴⁰UC Denver, Aurora, CO, USA. ⁴¹University of Michigan, Ann Arbor, MI, USA. ⁴²Stanford University School of Medicine, Stanford, CA, USA. ⁴³Sheba Medical Center, Ramat Gan, Israel. ⁴⁴Northwestern University, Chicago, IL, USA. ⁴⁵Washington University School of Medicine, St. Louis, WA, USA. ⁴⁶Centro Hospitalar Do Alto Ave, Epe, Guimaraes, Portugal. ⁴⁷Wexford Health and Wellness Pavilion, Pittsburgh, PA, USA. ⁴⁸University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA. ⁴⁹University Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. ⁵⁰The University of Utah Health Sciences Center, Salt Lake City, UT, USA. ⁵¹University of Alberta Foothills Medical Centre, Calgary, AB, Canada. ⁵²University of Alabama at Birmingham, Birmingham, AL, USA. ⁵³Charité Campus Rudolf-Virchow-Klinikum, Berlin, Germany. ⁵⁴Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain. ⁵⁵Johns Hopkins Hospital, Baltimore, MD, USA. ⁵⁶Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Pavia, Italy. ⁵⁷Institutul de Cardiologie Prof. Dr. C.

C. Iliescu Spitalului Fundeni, Bucharest, Romania. ⁵⁸University of Maryland, Baltimore, MD, USA. ⁵⁹Montefiore Medical Center-Jack D. Weiler Hospital, Bronx, NY, USA. ⁶⁰Instituto Dante Pazzanese De Cardiologia, Sao Paulo, Brazil. ⁶¹John Ochsner Heart & Vascular Institute, New Orleans, LA, USA. ⁶²University Hospital of RWTH Aachen, Aachen, Germany. ⁶³Johann-Gutenberg-Universität, Mainz, Germany. ⁶⁴Konkuk University Medical Center, Seoul, Republic of Korea. ⁶⁵Oregon Health and Science University, Portland, OR, USA. ⁶⁶Afdeling Klinische Cardiologie, O&N I, Louvain, Belgium. ⁶⁷Instituto De Investigaciones Medicas Dr Alfredo Lanari, Buenos Aires, Argentina. ⁶⁸Department of Neurology, Istanbul University, Istanbul, Turkey. ⁶⁹National Taiwan University Hospital, Taipei, Taiwan. ⁷⁰University of Chicago Medical Center, Chicago, IL, USA. ⁷¹Medical College of Wisconsin, Milwaukee, WI, USA. ⁷²Mayo Clinic Arizona, Phoenix, AZ, USA. ⁷³Department of Neurology, University of CA – San Francisco, San Francisco, CA, USA. ⁷⁴VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. ⁷⁵Advocate Christ Medical Centre, Oak Lawn, IL, USA. ⁷⁶University of Miami Hospital & Clinics, Miami, FL, USA. ⁷⁷Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina. ⁷⁸Chiba University Hospital, Chiba-shi, Japan. ⁷⁹Hospital Gregorio Marañón, Madrid, Spain. ⁸⁰Hospital Clinico San Carlos, Madrid, Spain. ⁸¹Wolfson Medical Center, Holon, Israel. ⁸²Temple University School of Medicine, Philadelphia, PA, USA. ⁸³Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus. ⁸⁴University of California Irvine, Orange, CA, USA. ⁸⁵NYU Medical Center, New York, NY, USA. ⁸⁶University of Pittsburgh Medical Center (UPMC), Pittsburgh, USA.

Received: 5 January 2022 Accepted: 8 May 2022

Published online: 18 June 2022

References

- Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. *J Am Coll Cardiol*. 2015;66:2451–66.
- Ando Y, Coelho T, Berk JL, Cruz MW, Ericson BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis*. 2013;8:31.
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73:2872–91.
- Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *J Neurol*. 2021;268:2109–22.
- Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis. 2015. <http://amyloidosismutations.com/mut-atrr.php>. Accessed 11 Oct 2021.
- Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail*. 2019;7:709–16.
- Conceição I, Coelho T, Rapezzi C, Parman Y, Obici L, Galan L, et al. Assessment of patients with hereditary transthyretin amyloidosis—understanding the impact of management and disease progression. *Amyloid*. 2019;26:103–11.
- Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. *Curr Med Res Opin*. 2013;29:77–84.
- Coelho T, Maurer MS, Suhr OB. THAOS—the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. *Curr Med Res Opin*. 2013;29:63–76.
- Gonzalez-Moreno J, Losada-Lopez I, Cisneros-Barroso E, Garcia-Pavia P, Gonzalez-Costello J, Munoz-Beamud F, et al. A descriptive analysis of ATTR amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey. *Neurol Ther*. 2021;10:833–45.
- Sekijima Y, Mundayat R, Ishii T, Ando Y. The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan. *Amyloid*. 2019;26:61–2.
- Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). *Eur Heart J*. 2019. <https://doi.org/10.1093/eurheartj/ehz173>.
- Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis:

- THAOS (Transthyretin Amyloid Outcome Survey). *J Am Coll Cardiol*. 2016;68:161–72.
14. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. *N Engl J Med*. 1997;336:466–73.
 15. Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. *Eur Heart J*. 1998;19:782–9.
 16. Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. *Eur Heart J*. 2012;33:1120–7.
 17. Almeida MR, Hesse A, Steinmetz A, Maisch B, Altland K, Linke RP, et al. Transthyretin Leu 68 in a form of cardiac amyloidosis. *Basic Res Cardiol*. 1991;86:567–71.
 18. Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. *Muscle Nerve*. 2017;55:323–32.
 19. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. *Arch Neurol*. 2002;59:1771–6.
 20. Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, et al. Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS. *JACC Heart Fail*. 2021;9:736–46.
 21. Batra J, Rosenblum H, Defilippis EM, Griffin JM, Saith SE, Gamino D, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile mutation: insights from noninvasive pressure-volume analysis. *J Card Fail*. 2021;27:67–74.
 22. Kroi F, Fischer N, Gezin A, Hashim M, Rozenbaum MH. Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. *Cardiol Ther*. 2021;10:41–55.
 23. Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. *Amyloid*. 2008;15:40–8.
 24. Santos D, Santos MJ, Alves-Ferreira M, Coelho T, Sequeiros J, Alonso I, et al. mtDNA copy number associated with age of onset in familial amyloid polyneuropathy. *J Neurol Neurosurg Psychiatry*. 2018;89:300–4.
 25. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail*. 2019;12: e006075.
 26. Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, et al. Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. *JACC CardioOncol*. 2021;3:537–46.
 27. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with Transthyretin Amyloid Cardiomyopathy. *N Engl J Med*. 2018;379:1007–16.
 28. Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379:11–21.
 29. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med*. 2018;379:22–31.
 30. Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. *Eur Heart J*. 2016;37:1826–34.
 31. Pastorelli F, Fabbri G, Rapezzi C, Serenelli M, Plasmati R, Vacchiano V, et al. Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. *Amyloid*. 2021;28:173–81.
 32. Wajnsztajn Yungheer F, Kim A, Boehme A, Kleyman I, Weimer LH, Maurer MS, et al. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. *J Peripher Nerv Syst*. 2020;25:265–72.
 33. Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary approaches for transthyretin amyloidosis. *Cardiol Ther*. 2021;10:289–311.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

